Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective Inhibitor

共价靶向导致LIMK1亚型选择性抑制剂的开发

阅读:13
作者:Sebastian Mandel ,Thomas Hanke ,Niall Prendiville ,María Baena-Nuevo ,Lena Marie Berger ,Frederic Farges ,Martin Peter Schwalm ,Benedict-Tilman Berger ,Andreas Kraemer ,Lewis Elson ,Hayuningbudi Saraswati ,Kamal R Abdul Azeez ,Verena Dederer ,Sebastian Mathea ,Ana Corrionero ,Patricia Alfonso ,Sabrina Keller ,Matthias Gstaiger ,Daniela S Krause ,Susanne Müller ,Sandra Röhm ,Stefan Knapp

Abstract

Selectivity for closely related isoforms of protein kinases is a major challenge in the design of drugs and chemical probes. Covalent targeting of unique cysteines is a potential strategy to achieve selectivity for highly conserved binding sites. Here, we used a pan-LIMK inhibitor to selectively probe LIMK1 over LIMK2 by targeting the LIMK1-specific cysteine C349 located in the glycine-rich loop region. Binding kinetics of both noncovalent and covalent LIMK inhibitors were investigated, and the fast on-rate and small size of type-I inhibitors were used in the design of a covalent LIMK1 inhibitor. The developed cell-active, isoform-selective LIMK1 inhibitor showed excellent proteome-wide selectivity in pull-down assays, enabling studies of LIMK1 isoform-selective functions in cellular model systems and providing a versatile chemical tool for studies of the LIMK signaling pathway.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。